Immunotherapy with interleukin-2 after autologous bone marrow transplantation (ABMT) for acute myelogenous leukemia (AML).

被引：0
|
作者：
Massumoto, CM [1 ]
Macedo, MCA [1 ]
Saboya, R [1 ]
Silva, R [1 ]
Loterio, H [1 ]
Dzik, C [1 ]
Pallotta, R [1 ]
Chamone, DAF [1 ]
Dulley, F [1 ]
机构：
[1] UNIV SAO PAULO,FUNDACAO PRO SANGUE HEMOCENTRO,DEPT HAEMATOL,BR-05508 SAO PAULO,BRAZIL
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4566 / 4566
页数：1
相关论文
共 50 条
  • [31] Immunotherapy of hematologic malignancies with autologous bone marrow transplant (ABMT) using in vitro interleukin-2 (IL-2)-treated bone marrow (BM).
    Margolin, K
    vanBesien, K
    Wright, C
    Woo, D
    Champlin, R
    Thomas, M
    Davis, M
    Grimm, E
    Forman, S
    BLOOD, 1995, 86 (10) : 1541 - 1541
  • [32] Thiotepa, busulfan, cyclophosphamide and autologous bone marrow transplantation (ABMT) for acute leukemia.
    Nagler, A
    Naparstek, E
    Or, R
    Varadi, G
    Slavin, S
    BONE MARROW TRANSPLANTATION, 1998, 21 : S98 - S98
  • [33] AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) FOR ACUTE-LEUKEMIA (AL) IN REMISSION
    CARELLA, AM
    SANTINI, G
    RIZZOLI, V
    PORCELLINI, A
    MARTINENGO, M
    CONGIU, A
    NATI, S
    GIORDANO, D
    SCARPATI, D
    CORVO, R
    FRANZONE, P
    RAFFO, MR
    SESSAREGO, C
    MARMONT, AM
    INTERNATIONAL JOURNAL OF CELL CLONING, 1985, 3 (04): : 247 - 248
  • [34] ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) OR AUTOLOGOUS BMT (ABMT) FOLLOWED BY INVIVO INTERLEUKIN-2 (IL2) FOR PATIENTS WITH ACUTE MYELOBLASTIC-LEUKEMIA (AML) IN 1ST REMISSION
    PRENTICE, HG
    HAMON, MD
    SMITH, OP
    GOTTLIEB, DJ
    GILMORE, M
    BARBOUR, VM
    MACDONALD, ID
    EXPERIMENTAL HEMATOLOGY, 1992, 20 (06) : 708 - 708
  • [35] MARROW TRANSPLANTATION FOR ACUTE MYELOGENOUS LEUKEMIA (AML) IN REMISSION
    THOMAS, ED
    BUCKNER, CD
    FEFER, A
    JOHNSON, FL
    NEIMAN, P
    SANDERS, J
    STORB, R
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 30 - 30
  • [36] Autologous bone marrow transplantation (ABMT) and one year maintenance therapy in childhood acute lymphoblastic (ALL) and acute myeloblastic leukemia (AML)
    Zintl, F
    Fuchs, D
    Hermann, J
    Muller, A
    Sauerbrey, A
    Hempel, L
    Gruhn, B
    Hafer, R
    Fuller, J
    BLOOD, 1995, 86 (10) : 355 - 355
  • [37] A phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow
    Vogler, WR
    Berdel, WE
    Geller, RB
    Brochstein, JA
    Beveridge, RA
    Dalton, WS
    Miller, KB
    Lazarus, HM
    PLATELET-ACTIVATING FACTOR AND RELATED LIPID MEDIATORS 2: ROLES IN HEALTH AND DISEASE, 1996, 416 : 389 - 396
  • [38] Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia (AL) in first complete remission.
    Blaise, D
    Attal, M
    Reiffers, J
    Michallet, M
    Bellanger, C
    Pico, JL
    Stoppa, AH
    Payen, C
    Marit, G
    Bouabdallah, R
    Sotto, JJ
    Rossi, JF
    Brandely, M
    Hercend, T
    Maraninchi, D
    BLOOD, 1999, 94 (10) : 77A - 77A
  • [39] INTERLEUKIN-2 IMMEDIATELY AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC-LEUKEMIA - A PHASE-I STUDY
    WEISDORF, DJ
    ANDERSON, PM
    BLAZAR, BR
    UCKUN, FM
    KERSEY, JH
    RAMSAY, NKC
    TRANSPLANTATION, 1993, 55 (01) : 61 - 66
  • [40] Purging autologous bone marrow with monoclonal antibodies for transplantation in acute myelogenous leukemia
    Hammert, LC
    Ball, ED
    BLOOD REVIEWS, 1997, 11 (02) : 80 - 90
12345